LSTA · Lisata Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | - | $0 | $70.0K | $0 | - | $0 | $0 | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.20M | - | $1.96M | $2.25M | $2.60M | - | $2.54M | $2.60M | $3.24M | - |
| SG&A | $3.25M | - | $2.46M | $2.69M | $3.25M | - | $2.79M | $2.92M | $3.36M | - |
| Total Operating Expenses | $4.94M | - | $4.41M | $4.94M | $5.85M | - | $5.34M | $5.52M | $6.60M | - |
| D&A | $2.0K | - | $44.0K | $44.0K | $43.0K | - | - | - | $46.0K | - |
| Operating Income | ($4.94M) | - | ($4.41M) | ($4.87M) | ($5.85M) | - | ($5.34M) | ($5.52M) | ($6.60M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($387.0K) | - | $0 | $0 | ($962.0K) | - | $0 | $0 | ($798.0K) | - |
| Net Income | ($4.49M) | - | ($4.25M) | ($4.66M) | ($4.72M) | - | ($4.93M) | ($5.04M) | ($5.40M) | - |
| EPS - Basic | ($0.50) | - | ($0.49) | ($0.54) | ($0.55) | - | ($0.59) | ($0.61) | ($0.65) | - |
| EPS - Diluted | ($0.50) | - | ($0.49) | ($0.54) | ($0.55) | - | ($0.59) | ($0.61) | ($0.65) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.06M | $15.96M | $19.00M | $16.84M | $20.22M | $16.21M | $19.51M | $28.29M | $21.80M | $22.59M |
| Accounts Receivable | - | $0 | - | - | - | $900.0K | - | - | - | $0 |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $510.0K | $1.02M | $619.0K | $782.0K | $602.0K | $1.28M | $556.0K | $728.0K | $1.26M | $2.42M |
| Current Assets | $14.02M | $17.70M | $21.57M | $24.89M | $28.62M | $34.58M | $37.69M | $41.98M | $47.56M | $53.92M |
| Total Assets | $14.06M | $17.74M | $21.76M | $25.16M | $28.98M | $35.00M | $38.20M | $42.57M | $48.24M | $54.69M |
| Current Liabilities | $3.31M | $3.07M | $4.57M | $4.31M | $3.81M | $5.61M | $4.69M | $4.46M | $5.33M | $6.59M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.39M | $3.14M | $4.64M | $4.38M | $3.88M | $5.68M | $4.76M | $4.58M | $5.50M | $6.80M |
| Stockholders' Equity | $10.93M | $14.86M | $17.37M | $21.03M | $25.36M | $29.57M | $33.69M | $38.25M | $43.00M | $48.15M |
| Retained Earnings | ($569.14M) | ($564.65M) | ($561.70M) | ($557.45M) | ($552.79M) | ($548.07M) | ($543.46M) | ($538.53M) | ($533.48M) | ($528.08M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($3.08M) | - | - | - | ($5.40M) | - | - | - | ($7.03M) | - |
| Investing Cash Flow | $0 | - | - | - | $9.43M | - | - | - | $6.44M | - |
| Financing Cash Flow | $181.0K | - | - | - | ($23.0K) | - | - | - | ($142.0K) | - |
| CapEx | $0 | - | - | - | $0 | - | - | - | - | - |
| Free Cash Flow | ($3.08M) | - | - | - | ($5.40M) | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | -6954.3% | - | - | - | - | - | - |
| EBITDA margin | - | - | - | -6891.4% | - | - | - | - | - | - |
| Net margin | - | - | - | -6655.7% | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.69 | - | - | - | 1.14 | - | - | - | - | - |
| R&D / Revenue | - | - | - | 3218.6% | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | 3835.7% | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -31.9% | - | -19.5% | -18.5% | -16.3% | - | -12.9% | -11.8% | -11.2% | - |
| Return on equity | -41.1% | - | -24.5% | -22.2% | -18.6% | - | -14.6% | -13.2% | -12.6% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.23 | 5.76 | 4.72 | 5.77 | 7.52 | 6.16 | 8.03 | 9.42 | 8.92 | 8.18 |
| Quick ratio | 4.23 | 5.76 | 4.72 | 5.77 | 7.52 | 6.16 | 8.03 | 9.42 | 8.92 | 8.18 |
| Cash ratio | 3.94 | 5.20 | 4.16 | 3.90 | 5.31 | 2.89 | 4.16 | 6.35 | 4.09 | 3.43 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.29 | 1.19 | 1.25 | 1.20 | 1.14 | 1.18 | 1.13 | 1.11 | 1.12 | 1.14 |
| Liabilities / Assets | 0.24 | 0.18 | 0.21 | 0.17 | 0.13 | 0.16 | 0.12 | 0.11 | 0.11 | 0.12 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 15.5% | - | 17.3% | 11.9% | 11.4% | - | 10.5% | 19.7% | 3.6% | - |
| Net income growth (YoY) | 5.0% | - | 13.8% | 7.6% | 12.5% | - | 6.3% | -25.3% | 12.7% | - |
| EPS growth (YoY) | 9.1% | - | 16.9% | 11.5% | 15.4% | - | 9.2% | -22.0% | 15.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 42.9% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -56.9% | -49.8% | -48.4% | -45.0% | -41.0% | -38.6% | -36.4% | -34.0% | -29.5% | -27.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$170.0K totalReportable Segment$170.0K · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing LISATA THERAPEUTICS against the 5 most active filers in the same SIC group.